Tevogen logo

Tevogen(NASDAQ) TVGNW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-83%
5 YearN/A
1 Year+32%
1 Month+52%
$0.08
+12.59%
+0.01Today
Tevogen last closing stock price
MetricPriceDate
Last closeUSD 0.082026-10-13
Tevogen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+29.87%USD 0.062026-10-06
1 month+51.93%USD 0.052026-09-11
3 month+43.88%USD 0.052026-07-15
Year to date+86.49%USD 0.042025-12-31
1 year+31.61%USD 0.062025-10-13
3 year+57.4%USD 0.052023-10-13
Since inception-82.51%USD 0.452022-01-03

Tevogen Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.61M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.87 (Low)

Price

$0.08

Volume

204,873

Open

$0.07

Previous Close

$0.08

Daily Range

$0.07 - $0.08

52-Week Range

$0.03 - $0.08

Estimated Earnings Date

Nov 24, 2026

TVGNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tevogen

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. The company aims to address unmet medical needs in virology, oncology, and neurological conditions, with its flagship product, TVGN 489, targeting severe cases of acute COVID-19 and long COVID.

Products and Services
  • Precision T cell therapies for acute COVID-19 and long COVID
  • Research and development in oncology and neurological conditions
  • Innovative treatment solutions for unmet medical needs
Growth Outlook
  • Strong focus on precision medicine aligns with industry trends
  • Potential market expansion as COVID-19 variants emerge
  • Increased investment in R&D to enhance product pipeline
Financial Highlights
  • Recent quarterly net income of -$5.76 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $1.08 million as of June 30, 2026
  • Trailing twelve months (TTM) cash flow from operations shows significant investment in growth
Tevogen Bio Holdings Inc. operates in a dynamic sector, with a commitment to developing innovative therapies that address critical health challenges. The company's focus on precision T cell therapies positions it well within the biotechnology landscape, particularly as the demand for effective treatments continues to rise. Recent financial data indicates a strategic investment in research and development, which is essential for long-term growth and market competitiveness. The current cash position provides a foundation for ongoing operations and future advancements in product development. As the healthcare industry evolves, Tevogen Bio Holdings Inc. remains poised to make significant contributions to patient care and treatment options.
AI Generated • Oct 8, 2026

Industry

Biotechnology

Headquarters

Warren, NJ 07059, US

TVGNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

248.50%

Return on Capital

N/A

Return on Assets

-457.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

204.87K

Avg. Volume

375.99K

Financials (TTM)

Gross Profit

-$204.98K

Operating Income

-$21.40M

EBITDA

-$20.95M

Operating Cash Flow

-$11.57M

Capital Expenditure

-$64.43K

Free Cash Flow

-$11.63M

Cash & ST Invst.

$1.08M

Total Debt

$3.04M

Tevogen Performance Analysis

Tevogen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Tevogen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.0%
Q42025-12-3120.0%
Q12026-03-31-34.2%
Q22026-06-305.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$60.14K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

18

N/A

Net Income

-$5.76M

-4.7%

EBITDA

-$5.60M

-2.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.08M

+57.9%

Total Debt

$3.04M

-59.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.06M

-80.9%

Short Term Debt

$1.98M

+0.0%

Return on Assets

-4.57%

N/A

Return on Invested Capital

15.04%

N/A

Free Cash Flow

-$3.01M

+5.8%

Operating Cash Flow

-$3.01M

+5.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRKRMarker Therapeutics, Inc.
$0.92-8.43%
COCPCocrystal Pharma, Inc.
$1.08+1.89%
PHIOPhio Pharmaceuticals Corp.
$0.93+1.36%
APMAptorum Group Limited
$8.26-14.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About TVGNW

What is the current price of Tevogen?

Tevogen is trading at $0.08 per share.

What is the 52-week range for Tevogen?

Over the past 52 weeks, Tevogen has traded between $0.03 and $0.08.

How much debt does Tevogen have?

Tevogen total debt is unavailable.

How much cash does Tevogen have on hand?

Tevogen does not have cash on hand data available.

What is Tevogen’s dividend yield?

Tevogen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.